New Drugs for NASH and HIV Infection: Great Expectations for a Great Need

Détails

ID Serval
serval:BIB_F4C60D19371B
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Editorial
Collection
Publications
Institution
Titre
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need
Périodique
Hepatology
Auteur⸱e⸱s
Guaraldi G., Maurice J. B., Marzolini C., Monteith K., Milic J., Tsochatzis E., Bhagani S., Morse C. G., Price J. C., Ingiliz P., Lemoine M., Sebastiani G., Shiver Network
ISSN
1527-3350 (Electronic)
ISSN-L
0270-9139
Statut éditorial
Publié
Date de publication
05/2020
Peer-reviewed
Oui
Volume
71
Numéro
5
Pages
1831-1844
Langue
anglais
Notes
Guaraldi, Giovanni
Maurice, James B
Marzolini, Catia
Monteith, Kenneth
Milic, Jovana
Tsochatzis, Emmanuel
Bhagani, Sanjay
Morse, Caryn G
Price, Jennifer C
Ingiliz, Patrick
Lemoine, Maud
Sebastiani, Giada
eng
Research Support, Non-U.S. Gov't
Hepatology. 2020 May;71(5):1831-1844. doi: 10.1002/hep.31177.
Résumé
In recent years, there has been an increasing number of clinical trials for the treatment of nonalcoholic steatohepatitis (NASH). People living with human immunodeficiency virus (PLWH) are commonly excluded from these studies, usually due to concerns over drug-drug interactions associated with antiretroviral therapy. The Steatohepatitis in HIV Emerging Research Network, a group of international experts in hepatology and infectious diseases, discusses our current understanding on the interaction between human immunodeficiency virus and NASH, and the issues related to the inclusion of PLWH in NASH clinical trials. Recent trials addressing NASH treatment in PLWH are discussed. The risk of drug-drug interactions between antiretroviral therapy and aramchol, cenicriviroc, elafibranor, obeticholic acid and resmetirom (MGL-3196), which are currently in phase 3 trials for the treatment of NASH, are reviewed. A model for trial design to include PLWH is proposed, strongly advocating for the scientific community to include this group as a subpopulation within studies.
Mots-clé
Anti-Retroviral Agents/therapeutic use, Chalcones/therapeutic use, Chenodeoxycholic Acid/analogs & derivatives/therapeutic use, Cholic Acids/therapeutic use, Clinical Trials, Phase III as Topic, Drug Interactions, HIV Infections/*complications/*drug therapy/epidemiology, Humans, Imidazoles/therapeutic use, Non-alcoholic Fatty Liver Disease/*complications/*drug therapy/epidemiology, Propionates/therapeutic use, Pyridazines/therapeutic use, Sulfoxides/therapeutic use, Uracil/analogs & derivatives/therapeutic use
Pubmed
Création de la notice
25/08/2023 5:17
Dernière modification de la notice
27/08/2023 6:01
Données d'usage